Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals

Antiviral Therapy

Volumn 10, Issue 4, 2005, Pages 563-573

  Costagliola, Dominique ^a   Potard, Valérie ^a   Duvivier, Claudine ^a,b   Pradier, Christian ^c   Dupont, Caroline ^d   Salmon, Dominique ^e   Duval, Xavier ^f  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e NONE   (France)

^f BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENOVIR PLUS RITONAVIR; ANTIRETROVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; TREATMENT FAILURE; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SALVAGE THERAPY;

EID: 23044478580     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD & EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
2. Rapport 2004 sous la direction du Pr JF Delfraissy. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d'experts. [Report under the direction of Professor JF Delfraissy. Therapeutic care for individuals infected by HIV. Recommendations of a group of experts]. 2004. Paris: Medecine-Sciences Flammarion.
3. Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vezinet F, Peytavin G, Costagliola D & Girard PM. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antiviral Therapy 2003; 8:427-434.
4. The Euroguidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. Journal of Acquired Immune Deficiency Syndromes 2001; 15:309-320.
5. Margot NA, Isaacson E, McGowan I, Cheng A & Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. Journal of Acquired Immune Deficiency Syndromes 2003; 33:15-21.
6. Gilleece YC, Qazi NA, Morlese JF, Mandalia S, Gazzard BG, Pozniak AL & Nelson MR. The efficacy of lopinavir in individuals experiencing protease inhibitor failure. Journal of Acquired Immune Deficiency Syndromes 2003; 32:238-240.
7. Brun-Vezinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M & Costagliola D. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003; 17:1795-1802.
8. Lanier ER, Ait-Khaled M, Scott J, Stone C, Melby T, Sturge G, St Clair M, Steel H, Hetherington S, Pearce G, Spreen W & Lafon S. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antiviral Therapy 2004; 9:37-45.
9. Masquelier B, Tamalet C, Montes B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferre V, Ruffault A, Palmer P, Trylesinsky A, Miller M, Brun-Vezinet F, Costagliola D & the ANRS AC11 resistance group. Genotypic determinants of the virological response to tenofovir DF in NRTI-experienced patients. Antiviral Therapy 2004; 9:315-323.
10. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A & Wulfsohn M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. Journal of Infectious Diseases 2004; 189:837-846.
11. Marcelin AG, Cohen-Codar I, King M, Guillevic E, Lamotte C, Chauvin JP, Kempf D, Peytavin G & Calvez V. Virological and pharmacological parameters predicting the response to LPV/r. 2nd IAS Conference on HIV Pathogenesis & Treatment. 13-16 July 2003, Paris, France. Abstract 827.
12. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R & Sun E. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antiviral Therapy 2002; 7:165-174.
13. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G & Calvez V; Genophar Study Group. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrobial Agents & Chemotherapy 2003; 47:594-600.
14. Lemeshow S & Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. American Journal of Epidemiology 1982; 115:92-106.
15. Mocroft A, Phillips AN, Friis-Moller N, Colebunders R, Johnson AM, Hirschel B, Saint-Marc T, Staub T, Clotet B & Lundgren JD. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from EuroSIDA study. Antiviral Therapy 2002; 7:21-30.
16. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, Tubiana R, Reynes J, Molina JM, Peytavin G, Calvez V & Costagliola D. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
17. Ledergerber B, Lundgren JD, Fusco JP, Weber R, Wit F, Castelli F, Staszewski S, Hogg R, Walker AS, Petoumenos K, d'Arminio Monforte A, Mussini C, Lampe F, Gil MJ & Phillips AN. Factors contributing to the success of ART following three class virological failure: The Plato Collaboration. 2nd IAS Conference on HIV Pathogenesis & Treatment. 13-16 July 2003, Paris, France. Abstract 576.
18. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM & Ho DD. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New England Journal of Medicine 1995; 333:1534-1539.
19. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B & Sterne JA. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
20. The PLATO Collaboration. Predictors of trend in CD4 positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three anti-retroviral drug classes. Lancet 2004; 364:51-62.
21. Squires K, Pozniak AL, Pierone Jr G, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF & Cheng A, for the Study 907 Team. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. A randomized trial. Annals of Internal Medicine 2003; 139:313-320.
22. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E & Cheng AK. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
23. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M & Purdon S. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS 2000; 14:781-789.
24. de Mendoza C, Martin-Carbonero L, Barreiro P, Diaz B, Valencia E, Jiménez-Nacher I, Gallego O, Nunez M, Gonzales-Lahoz J & Soriano V. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clinical Trials 2002; 3:304-309.
25. Boffito M, I. Arnaudo I, Raiteri R, Bonora S, Sinicco A, Digarbo A, Reynolds HE, Hoggard PG, Back DJ & Perri GD. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002; 16:2081-2083.
26. Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chene G, Clavel F & Girard PM. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clinical Pharmacology & Therapeutics 2004; 75:310-323.
27. Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G & Vilde JL. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrobial Agents & Chemotherapy 2002; 46:570-574.
28. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SDW, Clotet B, D'Aquila RT & Martinez-Picado J. Amprenavir-resistant HIV-1 exibits lopinavir cross-resistance and reduced replication capacity. Journal of Acquired Immune Deficiency Syndromes 2002; 16:1009-1017.
29. Parkin NT, Chappey C & Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 2003; 17:955-961.
30. Farthing C, Khanlou H & Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in treatment naive HIV-infected patients. Antiviral Therapy 2003; 8(Suppl 1):S195.
31. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN & Lundgren JD. Time to virological failure of 3 classes of anti-retrovirals after imitation of highly active antiretroviral therapy: results from the EuroSIDA study group. Journal of Infections Diseases 2004; 190:1947-1956.
32. Miller MD. K65R, TAMs and tenofovir. AIDS Reviews 2004; 6:22-33.